PubMed

High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease.

Jagannath S, Dicke KA, Armitage JO, Cabanillas FF, Horwitz LJ, Vellekoop L, Zander AR, Spitzer G.

Ann Intern Med. 1986 Feb;104(2):163-8.PMID: 3511811 [PubMed - indexed for MEDLINE]Related articles

Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.

Jagannath S, Armitage JO, Dicke KA, Tucker SL, Velasquez WS, Smith K, Vaughan WP, Kessinger A, Horwitz LJ, Hagemeister FB, et al.

J Clin Oncol. 1989 Feb;7(2):179-85.PMID: 2644397 [PubMed - indexed for MEDLINE]Related articles

High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.

Reece DE, Barnett MJ, Shepherd JD, Hogge DE, Klasa RJ, Nantel SH, Sutherland HJ, Klingemann HG, Fairey RN, Voss NJ, et al.

Blood. 1995 Jul 15;86(2):451-6.PMID: 7541661 [PubMed - indexed for MEDLINE]Related articlesFree article

Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.

Reece DE, Barnett MJ, Connors JM, Fairey RN, Fay JW, Greer JP, Herzig GP, Herzig RH, Klingemann HG, LeMaistre CF, et al.

J Clin Oncol. 1991 Oct;9(10):1871-9. Erratum in: J Clin Oncol 1992 Jan;10(1):170. PMID: 1919637 [PubMed - indexed for MEDLINE]Related articles

High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy.

Bierman PJ, Anderson JR, Freeman MB, Vose JM, Kessinger A, Bishop MR, Armitage JO.

Ann Oncol. 1996 Feb;7(2):151-6.PMID: 8777171 [PubMed - indexed for MEDLINE]Related articlesFree article

High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.

Nademanee A, O'Donnell MR, Snyder DS, Schmidt GM, Parker PM, Stein AS, Smith EP, Molina A, Stepan DE, Somlo G, et al.

Blood. 1995 Mar 1;85(5):1381-90.PMID: 7858268 [PubMed - indexed for MEDLINE]Related articlesFree article

Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.

Spinolo JA, Jagannath S, Velásquez W, Spitzer G, Cabanillas F, Hagemeister F, Horwitz LJ, Dicke KA.

Leuk Lymphoma. 1993 Jan;9(1-2):71-7.PMID: 8477204 [PubMed - indexed for MEDLINE]Related articles

Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.

Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE, et al.

J Clin Oncol. 1990 Apr;8(4):648-56.PMID: 2313334 [PubMed - indexed for MEDLINE]Related articles

Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.

Brice P, Gisselbrecht C, Ferme C, Lepage E, Baruchel A, Marolleau JP, Gerota O, Boiron M.

Nouv Rev Fr Hematol. 1991;33(3):267-72.PMID: 1956765 [PubMed - indexed for MEDLINE]Related articles

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).

Josting A, Kàtay I, Rueffer U, Winter S, Tesch H, Engert A, Diehl V, Wickramanayake PD.

Ann Oncol. 1998 Mar;9(3):289-95.PMID: 9602263 [PubMed - indexed for MEDLINE]Related articlesFree article

Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation.

Yahalom J, Gulati S.

Ann Oncol. 1991 Feb;2 Suppl 2:67-71.PMID: 2049322 [PubMed - indexed for MEDLINE]Related articles

Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy.

Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingemann HG, Nantel SH, O'Reilly S, Shepherd JD, Sutherland HJ, et al.

Blood. 1994 Mar 1;83(5):1193-9.PMID: 8118023 [PubMed - indexed for MEDLINE]Related articlesFree article

The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.

Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH.

Blood. 1993 Mar 1;81(5):1137-45.PMID: 8443375 [PubMed - indexed for MEDLINE]Related articlesFree article

High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease.

Kessinger A, Bierman PJ, Vose JM, Armitage JO.

Blood. 1991 Jun 1;77(11):2322-5. Erratum in: Blood 1991 Dec 15;78(12):3330. PMID: 1674890 [PubMed - indexed for MEDLINE]Related articlesFree article

High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease.

Ahmed T, Ciavarella D, Feldman E, Ascensao J, Hussain F, Engelking C, Gingrich S, Mittelman A, Coleman M, Arlin ZA.

Leukemia. 1989 Jan;3(1):19-22. Review.PMID: 2642573 [PubMed - indexed for MEDLINE]Related articles

Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.

Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP, et al.

J Clin Oncol. 1993 Jun;11(6):1085-91.PMID: 8099120 [PubMed - indexed for MEDLINE]Related articles

Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.

Taylor PR, Jackson GH, Lennard AL, Lucraft H, Proctor SJ.

Br J Cancer. 1993 Feb;67(2):383-7.PMID: 8431371 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.

Klumpp TR, Mangan KF, Glenn LD, Malaspina DR, Cropper T, Mullaney M, Macdonald JS.

Bone Marrow Transplant. 1993 Oct;12(4):337-45.PMID: 7506091 [PubMed - indexed for MEDLINE]Related articles

The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.

Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Kwak LW, Long GD, Stallbaum B, O'Connor P, Blume KG.

Ann Oncol. 1991 Jan;2 Suppl 1:47-50.PMID: 2043498 [PubMed - indexed for MEDLINE]Related articles

Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).

Wheeler C, Khurshid A, Ibrahim J, Elias A, Mauch P, Ault K, Antin J.

Leuk Lymphoma. 2001 Feb;40(5-6):499-509.PMID: 11426523 [PubMed - indexed for MEDLINE]Related articles